Current Status of the Role of PET Imaging in Diffuse Large B-Cell Lymphoma

Craig Moskowitz, Heiko Schöder

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

PET-CT (positron emission tomography-computed tomography) has emerged as an indispensable tool in the management of patients with diffuse large B-cell lymphoma (DLBCL). It is the standard imaging test for initial staging and is superior to CT in determining remission status and has replaced CT in this regard. The focus of this seminar will highlight controversial aspects on the role of PET-CT in the treatment of patients with DLBCL and will address the following questions: 1) Is a contrasted enhanced CT scan necessary for initial staging in the PET era? 2) Is a bone marrow biopsy required for initial staging of DLBCL in the era of PET imaging? 3) What is the role of interim PET in management? 4) Should PET scans be used for surveillance in patients in remission? 5) What is the role of semiquantitative PET and CT metrics in prognostication and response assessment?

Original languageEnglish (US)
Pages (from-to)138-142
Number of pages5
JournalSeminars in Hematology
Volume52
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Positron-Emission Tomography
Bone Marrow
Biopsy
Positron Emission Tomography Computed Tomography
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Current Status of the Role of PET Imaging in Diffuse Large B-Cell Lymphoma. / Moskowitz, Craig; Schöder, Heiko.

In: Seminars in Hematology, Vol. 52, No. 2, 01.01.2015, p. 138-142.

Research output: Contribution to journalReview article

@article{b6f1ce5dc4574f6fb46e155a10eca570,
title = "Current Status of the Role of PET Imaging in Diffuse Large B-Cell Lymphoma",
abstract = "PET-CT (positron emission tomography-computed tomography) has emerged as an indispensable tool in the management of patients with diffuse large B-cell lymphoma (DLBCL). It is the standard imaging test for initial staging and is superior to CT in determining remission status and has replaced CT in this regard. The focus of this seminar will highlight controversial aspects on the role of PET-CT in the treatment of patients with DLBCL and will address the following questions: 1) Is a contrasted enhanced CT scan necessary for initial staging in the PET era? 2) Is a bone marrow biopsy required for initial staging of DLBCL in the era of PET imaging? 3) What is the role of interim PET in management? 4) Should PET scans be used for surveillance in patients in remission? 5) What is the role of semiquantitative PET and CT metrics in prognostication and response assessment?",
author = "Craig Moskowitz and Heiko Sch{\"o}der",
year = "2015",
month = "1",
day = "1",
doi = "10.1053/j.seminhematol.2015.01.004",
language = "English (US)",
volume = "52",
pages = "138--142",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Current Status of the Role of PET Imaging in Diffuse Large B-Cell Lymphoma

AU - Moskowitz, Craig

AU - Schöder, Heiko

PY - 2015/1/1

Y1 - 2015/1/1

N2 - PET-CT (positron emission tomography-computed tomography) has emerged as an indispensable tool in the management of patients with diffuse large B-cell lymphoma (DLBCL). It is the standard imaging test for initial staging and is superior to CT in determining remission status and has replaced CT in this regard. The focus of this seminar will highlight controversial aspects on the role of PET-CT in the treatment of patients with DLBCL and will address the following questions: 1) Is a contrasted enhanced CT scan necessary for initial staging in the PET era? 2) Is a bone marrow biopsy required for initial staging of DLBCL in the era of PET imaging? 3) What is the role of interim PET in management? 4) Should PET scans be used for surveillance in patients in remission? 5) What is the role of semiquantitative PET and CT metrics in prognostication and response assessment?

AB - PET-CT (positron emission tomography-computed tomography) has emerged as an indispensable tool in the management of patients with diffuse large B-cell lymphoma (DLBCL). It is the standard imaging test for initial staging and is superior to CT in determining remission status and has replaced CT in this regard. The focus of this seminar will highlight controversial aspects on the role of PET-CT in the treatment of patients with DLBCL and will address the following questions: 1) Is a contrasted enhanced CT scan necessary for initial staging in the PET era? 2) Is a bone marrow biopsy required for initial staging of DLBCL in the era of PET imaging? 3) What is the role of interim PET in management? 4) Should PET scans be used for surveillance in patients in remission? 5) What is the role of semiquantitative PET and CT metrics in prognostication and response assessment?

UR - http://www.scopus.com/inward/record.url?scp=84925235555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925235555&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2015.01.004

DO - 10.1053/j.seminhematol.2015.01.004

M3 - Review article

C2 - 25805593

AN - SCOPUS:84925235555

VL - 52

SP - 138

EP - 142

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2

ER -